SITAJAN 50 Tablet is a high-quality oral antidiabetic formulation containing Sitagliptin 50 mg, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that plays a vital role in the management of type 2 diabetes mellitus. It functions by enhancing the body’s own incretin system, which improves the glucose-dependent release of insulin and suppresses glucagon production, resulting in better glycemic control without causing significant hypoglycemia or weight gain.
Sitagliptin is especially useful as monotherapy in patients inadequately controlled by diet and exercise or as part of combination therapy with other antidiabetic medications such as metformin, sulfonylureas, or thiazolidinediones. SITAJAN 50 Tablet offers an effective and well-tolerated treatment option that aligns with current clinical guidelines for type 2 diabetes management. It is usually taken once daily and has shown excellent results in reducing HbA1c levels over time.
Manufactured by Bluepill Express in WHO-GMP certified and ISO-compliant facilities, SITAJAN 50 ensures pharmaceutical-grade quality, consistency, and safety. The production process follows stringent international manufacturing protocols, including in-process testing, finished product validation, and rigorous documentation. Bluepill Express ensures that the tablets meet pharmacopeial standards in terms of content uniformity, dissolution profile, stability, and shelf-life.
The tablets are film-coated, easy to swallow, and produced with excipients that support optimal absorption and minimal gastrointestinal side effects. Custom packaging solutions are available for global export, including blister packs, alu-alu, and strip packaging, tailored to meet the regulatory and labeling requirements of each importing country. Each batch comes with a comprehensive dossier, including Certificate of Analysis (COA), Certificate of Pharmaceutical Product (COPP), stability studies, and CTD-format registration documents.
SITAJAN 50 is designed to be part of a patient’s long-term diabetes care plan, helping achieve better blood sugar control while maintaining cardiovascular safety. It does not typically require dose titration and offers the convenience of once-daily dosing with or without meals. Patients tolerate Sitagliptin well, and its use is associated with a low incidence of adverse effects, making it a favorable option in both initial and add-on therapy settings.
As a trusted pharmaceutical exporter and third-party manufacturer, Bluepill Express provides SITAJAN 50 to clients in Asia, Africa, Latin America, CIS countries, and the Middle East. The product complies with stringent export documentation and supports smooth product registration in regulated and semi-regulated markets. Our flexible production capacity and focus on international standards make Bluepill Express the partner of choice for clients seeking reliable, affordable, and effective diabetic medications.
Description provided by bluepill express.
FIEO Registered
Export Ready
